231 filings
Page 6 of 12
8-K
kg0qju
12 Aug 21
Motus GI Reports Second Quarter 2021 Financial Results and Provides Corporate Update
4:10pm
8-K
zvawok5w7eeq npg89u7
21 Jul 21
Motus GI Secures Expanded $12M Credit Financing to Support Growth Strategy
8:06am
DEFA14A
mvm7skvpj6j3q2s6eq1o
2 Jul 21
Additional proxy soliciting materials
4:17pm
8-K
al8cn buzt25bpy67avw
23 Jun 21
Motus GI Appoints Experienced Financial Biotech Executive, Sonja Nelson, to its Board of Directors and as Chair of Audit Committee
4:10pm
8-K
qt7 wkz5e5lsn
16 Jun 21
Motus GI Announces First Patients Enrolled in the European Union Feasibility Study
8:05am
8-K
yzlg3tu 4nhyp2r2eghq
3 Jun 21
Motus GI Announces Publication of Pure-Vu® System Clinical Data
8:11am
8-K
91gk8k2wv3 kbyfj1r
25 May 21
Implementation of the Pure-Vu System is designed to improve efficiencies and outcomes
8:05am
8-K
g4ejz zfx9600f
13 May 21
Motus GI Reports First Quarter 2021 Financial Results and Provides Corporate Update
4:10pm
8-K
loxlo bzuqm3fhizt7w3
7 May 21
Motus GI Announces Publication of a Pure-Vu System® Cost Effectiveness Analysis in the Journal of Cost Effectiveness and Resource Allocation
7:37am
8-K
meawx7 1zpefj
30 Apr 21
Motus GI Receives FDA Clearance to Market the Pure-Vu® System for Upper GI Endoscopy
10:45am
EFFECT
nmpciipnw5p51uhsgf
29 Mar 21
Notice of effectiveness
12:15am
EFFECT
bflv0yw0vwsdci2 gro
29 Mar 21
Notice of effectiveness
12:15am
424B3
lktn2
26 Mar 21
Prospectus supplement
4:43pm
424B5
ze42a276m0vjin7zwwn
26 Mar 21
Prospectus supplement for primary offering
4:41pm
CORRESP
x53zt
24 Mar 21
Correspondence with SEC
12:00am
CORRESP
oon17
24 Mar 21
Correspondence with SEC
12:00am